ClinicalTrials.gg
Status unknownNCT05841836Updated May 3, 2023

The Safety and Efficacy of the Suture-Mediated Closure System

An interventional study of the Suture-Mediated Closure System and Perclose ProGlide Suture-Mediated Closure System in Peripheral Arterial Disease and Arterial Puncture, sponsored by Zhejiang Zylox Medical Device Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Zhejiang Zylox Medical Device Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2022, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.

Planned enrollment
15th of 53
228 · median 167
Started
2022
with 7 others
No phase
34 of 80
13 open now
Registered
56th of 80
by date
Lead sponsor
6 of 80
Zhejiang Zylox Medical Device Co., Ltd.

Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 15th largest by planned enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2022, is one of 34 with no phase, and was the 56th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Peripheral Arterial Disease with a site in China, or all of them as a file.
02

Study summary

This was a prospective, multicenter, randomized, controlled, non-inferiority clinical study with the primary objective of validating the safety and efficacy of the Suture-Mediated Closure System for percutaneous closure of the common femoral artery puncture site.

Read the detailed description

This study was a prospective, multicenter, randomized, controlled, non-inferiority clinical trial. It is planned to be conducted in multiple clinical trial institutions and enroll 228 subjects. Eligible subjects were randomly divided into the experimental group or the control group at a ratio of 1:1.

03

Conditions studied

  • Peripheral Arterial Disease
  • Arterial Puncture
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 years old and 85 years old, randomized
  • Patients who can be examined or treated with a common femoral artery puncture interventional catheter using a 5F to 22F sheath tube
  • Patient(or their guardians) who submitted a written for the this trial

Exclusion criteria

Exclusion Criteria:

  • Known to be pregnant or lactating
  • The diameter of femoral artery on the puncture side was less than 5mm
  • Patients requiring anterograde puncture approach
  • Have participated in or plan to participate in another clinical trial in the same period
  • Known allergy to any components of the device, and/or to contrast agents and anticoagulants
  • (INR) >2.0
  • Traumatic vascular injury at the approach site
  • Systemic or local groin infection
  • Cerebrovascular accident or myocardial infarction within 3 months
  • An arterial catheter needs to be placed at the access site
  • Morbidly obese ( ≥40 kg/m2)
  • The entire common femoral artery wall assessed by ultrasound, calcification located in the anterior wall cut, the extent of more than 50% circumferential or common femoral artery stenosis ≥50
  • Femoral artery aneurysm, arteriovenous fistula or pseudoaneurysm in common femoral artery
  • Using a clip vessel occluder at the past ipsilateral femoral artery access site
  • Use of a puncture point occlusion device at the ipsilateral femoral access site within the past 30 days
  • Underwent an intervention via ipsilateral femoral artery puncture within the past 30 days or within the next 30 days
  • Ipsilateral femoral vein sheath needed to be used
  • Evidence of previous common femoral artery surgery on the same side (e.g., inguinal incision)
  • Hematoma at ipsilateral arterial access
  • Other circumstances that the investigator deemed inappropriate for participation in the trial.femoral artery aneurysm, arteriovenous fistula or pseudoaneurysm in common femoral artery
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    the Suture-Mediated Closure System

    Produced by Zhejiang Zylox Medical Device Co., Ltd.

    Device: the Suture-Mediated Closure System

  • Active comparator
    Perclose ProGlide Suture-Mediated Closure System

    Perclose® ProGlide Suture-Mediated Closure System

    Device: Perclose ProGlide Suture-Mediated Closure System

Interventions

  • Devicethe Suture-Mediated Closure System

    To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site

  • DevicePerclose ProGlide Suture-Mediated Closure System

    To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site

06

What researchers measure

Primary outcomes

  1. Incidence of major complications at the access site

    The number of subjects who experienced major complications as a proportion of the total number of subjects who used the vascular stapler system

    Time frame: 30 days after the procedure

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for May 2023, 7 months after the start.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 7 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2023
First posted
May 3, 2023
StartActual
Oct 26, 2022
Primary completionEst.
May 30, 2023
CompletionEst.
Jul 30, 2023
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05841836
Lead sponsor
Zhejiang Zylox Medical Device Co., Ltd.
Responsible party
Sponsor
First posted
May 3, 2023
Start date
Oct 26, 2022
Primary completion
May 30, 2023 (estimated)
Completion
Jul 30, 2023 (estimated)
Last update
May 3, 2023

Study contacts

Yu Zhao, Master
Contact
820994765@qq.com
13808338199
Yu Zhao, Master
principal investigator · First Affiliated Hospital of Chongqing Medical University
Hongfei Sang, M.D.
principal investigator · Second Affiliated Hospital of Soochow University
Jianming Sun, M.D.
principal investigator · The Second Affiliated Hospital of Chongqing Medical University
Changsheng Shi, Master
principal investigator · Ruian People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion